- Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
For: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
This study looks at a new drug, 177Lu-TLX591, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It compares this new drug combined with standard treatments to standard treatments alone.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Canada - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
For: NSCLC (Non-small Cell Lung Cancer) · Non-Small Cell Lung Cancer · NSCLCUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
For: Prostate Cancer · Prostatic NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.
For: Neoplasms · Child · AdolescentUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
This study is testing new treatments, alone or in combination, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if these treatments are safe and effective in helping men with this condition.
For: Castration-Resistant Prostatic Cancer · MetastasisUnited States · Argentina · Australia - RecruitingPHASE3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
This study is for people with advanced lung cancer that has stopped responding to certain immune system treatments. It tests a new treatment called OSE2101 against a standard chemotherapy, Docetaxel, to see which works better. This is a large study trying to find new ways to help patients.
For: Patients With Non-Small Cell Lung CancerUnited States · Belgium · Canada - Active not recruitingPHASE2
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
This study is looking at new combinations of medicines for advanced lung cancer. It aims to see how well different immunotherapy treatments work together and how safe they are for patients. The goal is to find better ways to treat this type of lung cancer.
For: Advanced Non-Small Cell Lung CancerUnited States · Australia · France - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
For: Non-small Cell Lung Cancer (NSCLC)United States · Australia · Brazil - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy after surgery for certain types of womb cancer (endometrial cancer). We want to see if this combination helps stop the cancer from coming back and helps people live longer compared to chemotherapy alone.
For: Endometrial NeoplasmsUnited States · Argentina · Austria - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This study looks at a new drug, Giredestrant, combined with an existing treatment called Phesgo, for advanced breast cancer. It aims to see if this new combination is safe and works better than Phesgo alone for people with specific types of breast cancer.
For: Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This study compares a new cancer drug called sigvotatug vedotin with a standard treatment, docetaxel, for advanced non-small cell lung cancer that has previously been treated. It aims to see if the new drug works better and what side effects it might cause.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE2
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
This study compares a new treatment, 177Lu-PSMA-617, with standard chemotherapy (docetaxel) for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new treatment can better slow cancer growth.
For: Prostate CancerCanada - RecruitingPHASE3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
This study is looking at a new treatment, Xaluritamig, combined with Abiraterone, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It compares this combination to standard treatments to see if it helps men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
For: Non Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
This study is looking for new treatments for advanced squamous non-small cell lung cancer that hasn't responded to usual treatments. Researchers are testing new medicines called antibody drug conjugates (ADCs) to see if they can shrink the cancer and if they are safe.
For: Lung NeoplasmUnited States · Chile · China - RecruitingPHASE2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, Inavolisib, combined with Enzalutamide for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to other standard treatments.
For: Metastatic Castration-Resistant Prostate CancerUnited States · Australia · Brazil - Active not recruitingPHASE2, PHASE3
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
This study, called STAMPEDE, looks for better ways to treat prostate cancer that is spreading or has a high chance of spreading. It tests new treatments against standard ones to help men live longer and have a better quality of life.
For: Prostate CancerSwitzerland · United Kingdom - Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread and is no longer responding to hormone treatment. We want to see if it works better and is safer than standard treatments chosen by doctors.
For: Metastatic Castration-resistant Prostate CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT
This study looks at treating a certain type of throat cancer with chemotherapy and radiotherapy to try and save the voice box. We're comparing two ways of giving chemotherapy to see which works better to keep the voice box working for longer.
For: Head and Neck Squamous Cell CarcinomaFrance - RecruitingPHASE2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
This study is for people with advanced lung cancer that has spread. It tests new treatments using a drug called Visugromab, combined with Nivolumab and sometimes Docetaxel, to see if they can work better than existing options.
For: Metastatic Non-Squamous Non-Small Cell Lung Cancer · Adult Solid TumorUnited States · Germany · Italy - Active not recruitingPHASE3
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
This study compares two ways of giving a prostate cancer drug, Docetaxel, along with standard treatments Darolutamide and ADT. It aims to find out which schedule causes fewer serious side effects in men with advanced prostate cancer.
For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Austria · Germany - Active not recruitingPHASE3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
This study looks at a new combination of drugs, ceralasertib and durvalumab, for people with advanced lung cancer that has grown after previous treatments. It compares this new combination to a standard chemotherapy drug, docetaxel, to see which works better and is safer.
For: Advanced or Metastatic Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
This study looks at new treatments for ovarian cancer that has come back and is resistant to platinum-based chemotherapy. It combines existing drugs like paclitaxel and bevacizumab with a new drug called pembrolizumab, hoping to stop the cancer from growing for longer.
For: Ovarian Cancer · Carcinoma, Ovarian Epithelial · Fallopian Tube NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
This study is testing a new medicine, Anvumetostat, for people with advanced cancers that are missing a specific gene called MTAP. Researchers want to find the safest dose, see how well it works, and understand its side effects, sometimes given with another cancer drug called Docetaxel.
For: Advanced MTAP-null Solid TumorsUnited States · Australia · Austria - RecruitingPHASE1
A Study of ASP3082 in Adults With Advanced Solid Tumors
This study looks at a new drug, ASP3082, for adults with advanced solid cancers that have a specific genetic change called KRAS G12D. It checks how safe the drug is and what dose works best, sometimes with another drug called cetuximab.
For: Solid TumorUnited States · China · France - Active not recruitingPHASE3
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study looks at a new medicine, sacituzumab tirumotecan, for advanced stomach or oesophagus cancer. It compares this new medicine to standard treatments to see if it's safer and works better for patients who have already had other treatments.
For: Gastroesophageal CancerUnited States · Belgium · Brazil - RecruitingPHASE2
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
This study is testing a new drug, pumitamig, with chemotherapy (docetaxel) for advanced non-small cell lung cancer that has worsened after previous treatment. It aims to check the safety and how well the combination works.
For: Non-small Cell Lung CancerUnited States · Australia · South Korea - Active not recruitingPHASE3
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
This study compares a new medicine, AMG 510 (also called Sotorasib), with a standard chemotherapy, Docetaxel, for people with a specific type of lung cancer. It's for advanced non-small cell lung cancer that has a particular genetic change called KRAS G12C and has already been treated.
For: KRAS p, G12c Mutated /Advanced Metastatic NSCLCUnited States · Australia · Belgium - RecruitingPHASE2
Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
This study looks at a new way to treat throat cancer caused by HPV. It uses chemotherapy first, followed by robotic surgery, to try and avoid harsh radiotherapy and its long-term side effects. The goal is to improve recovery and quality of life for patients.
For: Oropharynx Cancer · Tonsil Cancer · Throat CancerCanada - RecruitingPHASE1, PHASE2
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
This study is testing a new drug, BMS-986340, by itself and with other treatments for different advanced cancers. Researchers want to find the safest dose and see how well it works. This is the first time BMS-986340 has been tried in people.
For: Cervical Cancer · Gastric/Gastroesophageal Junction Adenocarcinoma · Microsatellite Stable Colorectal CancerUnited States · Australia · Canada - Active not recruitingPHASE2
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
This study compares a new drug, atezolizumab, plus standard chemotherapy (FLOT) against FLOT alone for stomach or food pipe cancer. It focuses on patients whose cancer shows certain immune markers, aiming to see if the new combination is safer and more effective before and after surgery.
For: Gastric Cancer · Gastroesophageal Junction AdenocarcinomaGermany · Switzerland - RecruitingPHASE3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
This study compares a new drug called tepotinib with standard treatments for advanced lung cancer. It's for people whose cancer has a specific change (MET Exon 14 mutation) and has already been treated. The aim is to see if tepotinib works better to stop the cancer from growing.
For: Advanced Non Small Cell Lung Cancer · MET Exon 14 MutationFrance - RecruitingPHASE1, PHASE2
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
This study is looking at new ways to treat advanced prostate cancer that has spread. Researchers are testing different medicines to see how safe they are, if they have side effects, and how well they work in men whose cancer hasn't responded to previous treatments.
For: Metastatic Prostate CancerUnited States · Australia · Germany - Active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
For: Urothelial CancerUnited States · Argentina · Australia - RecruitingPHASE3
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
This study looks at a new drug, gotistobart, for advanced non-small cell lung cancer that has worsened after previous PD-1/PD-L1 treatment. It compares gotistobart to standard chemotherapy (docetaxel) to see if it can help people live longer.
For: Non Small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
This study looks at new treatments for prostate cancer that has spread. It compares two new approaches with the usual care, hoping to improve how long people live and slow the cancer's spread. It's for men aged 18+.
For: Prostate Cancer MetastaticUnited Kingdom - Active not recruitingPHASE2
Study of Novel Treatment Combinations in Patients With Lung Cancer
This study looks at new drug combinations to treat lung cancer. It has three parts: for cancer that has spread, cancer that has grown despite previous treatment, and earlier-stage cancer that can be removed by surgery.
For: Lung Cancer · Advanced or Metastatic Non-Small-Cell Lung Cancer · Resectable Non-Small-Cell Lung CancerUnited States · Brazil · Hong Kong - Active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Brazil · Canada - Active not recruitingPHASE1, PHASE2
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
This study is testing a new combination of two medicines, amivantamab and docetaxel, for people with advanced non-small cell lung cancer. The aim is to find the best dose and see how well this combination works.
For: Carcinoma, Non-Small-Cell LungUnited States · Taiwan · Turkey (Türkiye) - Active not recruitingPHASE3
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study compares a new drug, Sacituzumab Govitecan, with a standard treatment, Docetaxel, for people in the UK with advanced non-small cell lung cancer that has already spread and hasn't responded to previous treatments.
For: Non-Small Cell Lung CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study compares a new drug, DS-1062a, with a standard chemotherapy, docetaxel, for advanced lung cancer. It's for people whose cancer has grown after previous treatments. We want to see if DS-1062a is safer and works better.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
This study looks at new drug combinations for advanced non-small cell lung cancer that has progressed after standard treatments. It compares adding new medicines, cobolimab and dostarlimab, to docetaxel chemotherapy, to see if they work better together.
For: Lung Cancer, Non-Small CellUnited States · Argentina · Australia - Active not recruitingPHASE2
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
This study looks at new ways to treat a type of breast cancer called HER2-positive. We're testing if using special drugs (Herceptin and Perjeta) without chemotherapy first can shrink tumours effectively. We're also checking if scans can predict how well treatments work.
For: Breast CancerBelgium · France · Germany - Not yet recruitingPhase III
A large clinical trial testing different combinations of hormone treatments, with or without chemotherapy called docetaxel, in men with advanced prostate cancer whose prostate-specific antigen levels haven’t dropped enough after 6 months of treatment
This study, called INTENSIFY, looks at adding chemotherapy early to standard hormone treatment for men with advanced prostate cancer whose blood test (PSA) hasn't dropped enough. It aims to see if this helps them live longer.
For: Metastatic prostate cancerUnited Kingdom